Introduction: FDA Regulation of Compounded Drugs
The FDA's approach to regulating compounded drugs operates under a specific interim policy that recognizes both the value of pharmacy compounding and the need for patient safety. The Category 2 list sits at the center of this regulatory framework, directly affecting the availability of compounds like BPC-157 in the United States.
For researchers, clinicians, and anyone involved in the peptide research community, understanding what Category 2 designation means-and what it does not mean-is essential for accurate interpretation of regulatory status and practical availability of research compounds.
Background: Pharmacy Compounding Regulations
The FDASIA and 503A/503B Framework
In 2013, Congress passed the FDA Safety and Innovation Act (FDASIA), which established section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. These sections created two categories of compounding pharmacies in the United States:
- 503A Pharmacies: Traditional compounding pharmacies that prepare patient-specific compounded drugs (made-to-order for individual patients)
- 503B Pharmacies: Outsourcing facilities that compound drugs in bulk and distribute them to healthcare providers and other pharmacies before patient-specific orders
The distinction between 503A and 503B is important: 503A pharmacies respond to individual patient prescriptions, while 503B pharmacies operate more like manufacturers, preparing bulk quantities in advance of specific orders.
The Traditional Compounding Model
Historically, 503A compounding pharmacies could only prepare medications in response to patient-specific prescriptions. This created a limitation: if a medication was difficult to obtain or not available from pharmaceutical manufacturers, a patient-specific prescription would need to exist before a pharmacy could prepare a compounded version.
This model worked well for some situations (e.g., customizing a patient's dosage or combining medications) but created bottlenecks when compounds were in genuine short supply or required preparation time.
The Interim Policy on Compounded Drugs Prepared in Advance
What the Policy Allows
In 2023, the FDA published an interim policy allowing compounding pharmacies (specifically 503B outsourcing facilities and some 503A pharmacies under state board authorization) to prepare certain drugs in advance of receiving patient-specific orders. This represented a significant regulatory shift.
Rather than waiting for a specific patient prescription, authorized pharmacies could now prepare and store certain compounded drugs in anticipation of future demand. This advance compounding applies specifically to drugs on the FDA's Category 1 or Category 2 lists.
Who This Affects
This interim policy primarily affects 503B outsourcing facilities, which are explicitly authorized to engage in advance compounding. Some 503A traditional compounding pharmacies may also engage in limited advance compounding, but this requires specific state board authorization and comes with additional oversight requirements.
Understanding Category 1 and Category 2
Category 1: Drugs in Shortage
Category 1 consists of drugs that are in shortage according to FDA's drug shortage list. These are typically FDA-approved drugs that manufacturers are unable to provide in sufficient quantities to meet patient demand. Examples include certain cancer medications, antibiotics, or other pharmaceuticals where supply chain disruptions have created genuine shortages.
Compounding pharmacies have long been authorized to compound Category 1 drugs to address shortages, and the interim policy simply clarifies that advance compounding is permitted for these purposes.
Category 2: Drugs Demonstrably Difficult to Obtain
Category 2 is more significant and more controversial. This list includes drugs that the FDA has determined are "demonstrably difficult to obtain," meaning they are not available from pharmaceutical manufacturers even though they may be FDA-approved or at least legally obtainable, and there is evidence of clinical or research demand.
The FDA's assessment for Category 2 status involves evaluating whether:
- The drug is not commercially available from pharmaceutical manufacturers
- There is documented evidence of clinical need or demand
- The drug could be safely and effectively compounded
- Compounding would address a genuine gap in availability
BPC-157 and FDA Category 2 Designation
When and Why Was BPC-157 Added?
BPC-157 was added to the FDA Category 2 list in September 2023. This designation reflected the FDA's determination that BPC-157 was demonstrably difficult to obtain and that permitting compounding pharmacies to prepare it in advance would serve a legitimate purpose.
The FDA's rationale for Category 2 listing likely included:
- BPC-157 is not available from FDA-approved pharmaceutical manufacturers
- There is documented demand from researchers, clinicians, and interested parties
- BPC-157 is a legitimate research compound with published preclinical data
- Compounding pharmacies could reliably produce BPC-157 to consistent standards
What This Means Practically
After the September 2023 Category 2 addition, state pharmacy boards in participating states could authorize compounding pharmacies to prepare BPC-157 in advance and maintain inventory. Before this designation, compounding pharmacies could technically prepare BPC-157 only in response to a specific patient or research order; after, they could prepare and stock it like they would a pharmaceutical ingredient in short supply.
This increased convenience and availability for researchers and practitioners who wished to obtain BPC-157 through compounding pharmacies, as they no longer needed to wait for individual compounding events.
What "Demonstrably Difficult to Obtain" Actually Means
It Is Not FDA Approval
The most critical misconception to address: Category 2 designation does NOT mean the FDA has approved BPC-157, determined it is safe, or confirmed it is effective for any medical use. It is a purely regulatory designation related to availability and compounding permissions.
It Does Not Imply Efficacy or Safety Confirmation
The FDA making a determination that a drug is "demonstrably difficult to obtain" is a logistical and regulatory finding, not a clinical endorsement. It means the FDA has determined that compounding pharmacies preparing it would serve a useful purpose, not that the FDA endorses the compound's safety or efficacy.
It Is Not the Same as an Approved Drug
Drugs on the FDA's approved pharmaceutical list (such as semaglutide or tirzepatide) have undergone extensive clinical trials, FDA review, and approval for specific indications. Category 2 drugs have undergone no such review. The FDA approval process and Category 2 compounding designation are entirely separate regulatory pathways.
How Category 2 Affects Compounding Pharmacies
503B Outsourcing Facilities
For 503B outsourcing facilities, Category 2 designation means they can now prepare BPC-157 in bulk and distribute it to healthcare providers, research facilities, and other legitimate organizations without requiring individual patient-specific prescriptions. This streamlines operations and allows inventory management.
503A Compounding Pharmacies
503A traditional compounding pharmacies' ability to advance-compound Category 2 drugs varies by state. Some state boards of pharmacy have authorized advance compounding of Category 2 drugs; others have not. Practitioners should verify their specific state's rules regarding advance compounding of Category 2 substances.
Oversight and Standards
Compounding pharmacies preparing Category 2 drugs must still comply with all applicable USP (United States Pharmacopeia) standards, state pharmacy board regulations, and FDA quality expectations. The Category 2 designation does not reduce oversight or quality standards-it simply permits advance compounding.
The Current Category 2 List
Known Category 2 Entries
As of the publication date of this article, known drugs on the Category 2 list include BPC-157 and potentially others, though the FDA's public listing of all Category 2 drugs is not exhaustively detailed in all publicly available sources. Practitioners should consult the FDA's official interim policy and regular updates for the complete and current list.
How to Check Current Status
The FDA publishes updates to the Category 2 list on a regular basis. To verify current Category 2 status for any compound, researchers should:
- Visit the FDA's official website and search for "interim policy on compounded drugs"
- Review Federal Register notices for category updates
- Contact state pharmacy boards directly for state-specific rules on advance compounding
- Consult with compounding pharmacies about their specific authorizations
Practical Implications for Researchers
Increased Availability
Category 2 designation has increased the practical availability of BPC-157 through compounding pharmacies. Researchers can more readily obtain BPC-157 without navigating complex individual ordering processes.
Quality and Standards Considerations
Because compounded drugs are not subject to the same FDA approval process as pharmaceutical drugs, researchers should verify compounding pharmacy credentials, understand USP standards compliance, and consider requesting certificates of analysis or quality documentation from compounding sources.
Documentation and Regulatory Clarity
Researchers working with compounded drugs should maintain clear documentation of the source, intended use, and regulatory basis for their research. Category 2 designation provides clearer regulatory standing for compounding but does not eliminate the need for appropriate research protocols and institutional oversight.
No Indication of Efficacy or Safety
Researchers must maintain clear separation between the regulatory fact (Category 2 designation allows compounding) and the scientific question (Does BPC-157 actually produce clinically meaningful effects in humans?). The regulatory designation does not answer the scientific question. See our article on BPC-157: Research Overview for detailed information on the evidence landscape.
Comparing Category 2 to FDA-Approved Drugs
To contextualize Category 2 designation, consider how it compares to FDA pharmaceutical approval:
- FDA-Approved Drugs (e.g., semaglutide): Have undergone Phase I, II, III clinical trials, FDA review, and approval for specific medical indications. Manufactured by approved pharmaceutical companies under FDA oversight. Safety and efficacy are established in human subjects.
- Category 2 Compounded Drugs (e.g., BPC-157): Are not FDA-approved. Are prepared by compounding pharmacies to USP standards. Have no Phase III clinical trials in humans. Regulatory designation reflects availability accommodation, not clinical vetting.
2026 Update: HHS Signals a Possible Reclassification
On The Joe Rogan Experience #2461, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides currently on the FDA's Category 2 list are expected to be moved back to Category 1. If implemented, this would restore the legal pathway for licensed compounding pharmacies to prepare these compounds under physician prescription.
Direct quote: "Our position is that the FDA has a job: just do the science on these kinds of issues and then tell the public what they've learned from the science, but don't tell physicians what they can and cannot prescribe."
Coverage: NPR · Gizmodo · MIT Technology Review
Policy announcement, not clinical evidence or FDA approval. Reclassification to Category 1 would expand compounding access; it does not establish efficacy or safety. For educational purposes only.
What this means in practice: Reclassification to Category 1 would restore the legal pathway for licensed compounding pharmacies to prepare these peptides for patients under physician prescription. It is distinct from full FDA approval. As of the date on this page, no formal rule change has been published in the Federal Register yet; this is a stated HHS policy direction. Check our FDA Status Tracker for the latest status.
Future Changes and Monitoring
Category Status May Change
The FDA retains the authority to remove compounds from the Category 2 list if circumstances change-for example, if a commercial pharmaceutical manufacturer began producing BPC-157, it might be removed from Category 2 status, as it would no longer be "demonstrably difficult to obtain."
Continued Regulatory Evolution
The interim policy on advance compounding is subject to review and potential modification. The FDA may expand, restrict, or clarify the policy based on emerging evidence, safety concerns, or operational experience.
State-Level Variations
Because pharmacy regulation is largely a state matter, Category 2 implementation may vary by state. Some states may more readily authorize advance compounding, while others may maintain more restrictive approaches. Researchers should verify state-specific rules.
Conclusion: Category 2 as a Regulatory Framework
The FDA Category 2 list serves an important function in pharmacy regulation, permitting advance compounding of drugs that are difficult to obtain through traditional pharmaceutical manufacturing. BPC-157's addition to the Category 2 list in September 2023 reflects the FDA's regulatory determination that compounding availability serves a legitimate purpose.
However, it is crucial that researchers, practitioners, and anyone working with Category 2 compounds understand what this designation does and does not imply. It permits compounding but does not confirm efficacy, does not imply safety approval, and does not represent clinical validation of the compound.
Practitioners and researchers should evaluate Category 2 compounds based on their scientific evidence base (see our BPC-157 research overview for an example) and understand the distinction between regulatory accommodation (which Category 2 provides) and clinical evidence (which must be evaluated separately).
For current information on Category 2 status and compounding regulations, consult the FDA's official sources and your state's pharmacy board.